Dupilumab improved exacerbations and lung function in patients with COPD and T2 inflammation, regardless of baseline BODE index score.

Patients with severe asthma initiated dupilumab and tezepelumab treatment more often than other biologics between 2022 and ...

A study found that children with early-onset atopic dermatitis have a higher risk of developing uveitis and should be closely ...

A prospective registry study found a greater risk for infections associated with JAK inhibitors in adolescents and adults with moderate to severe atopic dermatitis compared with biologics.

A cohort study finds children with early-onset atopic dermatitis to be at increased risk for uveitis, highlighting a need for ophthalmologic monitoring in youth.

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

18 months after saying "no" to regular NHS funding for Sanofi and Regeneron's Dupixent (dupilumab) for severe asthma in initial guidance, NICE has now backed the drug. The final appraisal ...

The deal builds on Sanofi's already formidable presence in immunological diseases currently spearheaded by Dupixent (dupilumab), its $14 billion blockbuster that targets diseases associated with ...

Desentum’s Phase I trial saw nearly all patients in the trial reaching their targeted maximum dose of pollen allergy vaccine, ...

Combining Deep Pruritus Relief, Effective Skin Clearance, and a Well-tolerated Safety ProfileHONG KONG, Apr 9, 2025 - (ACN Newswire) - SinoMab BioScience ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...